3,4,5-Trifluorophenylboronic acid

We are 3,4,5-Trifluorophenylboronic acid CAS:143418-49-9 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3,4,5-Trifluorophenylboronic acid
CAS.NO:143418-49-9
Synonyms:3,4,5-Trifluorophenylboronic acid
(3,4,5-trifluorophenyl)boronic acid
Molecular Formula:C6H4BF3O2
Molecular Weight:175.90100
 
Physical and Chemical Properties:
Density:1.44
Boiling point:263.6ºC
Flash point:113.2ºC
Index of Refraction:1.423-1.425
 
Specification:
Appearance:White to off-white crystalline solid 
Assay:≥98.0%
Moisture:≤0.2%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

3,4,5-Trifluorophenylboronic acid


Related News: Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.1645-65-4 By drawing these distinctions between APIs and the drugs themselves, manufacturers are able to specialize and pharmacists able to align generic equivalents with brand names.octane-1,8-diol Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).3-(Methylthio)propyl acetate CAS:16630-55-0 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology.

Related Products
Product Name
5-Fluoro-6-Methylpyridin-2-aMine View Details
Diphenylsilanediol View Details
[3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate View Details
2-Chloro-5-fluoro-3-methylpyridine manufacturer 1-Bromohexadecane manufacturer 1,4-dichlorobenzene manufacturer 3,6-dichloro-2-hydroxybenzoic acid manufacturer 2-(4-bromophenyl)triphenylene manufacturer